AvenCell was launched in 2021 by Blackstone Life Sciences, Cellex Cell Professionals and Intellia Therapeutics to create an offering that leverages switchable universal T-cell technology developed by the former Cellex subsidiary GEMoaB GmbH, with a license to Intellia’s proprietary CRISPR/Cas9-based allogeneic platform. The combined entity is the first of its kind to integrate a Switchable CAR-T with an off-the-shelf solution for applications across cancer and auto-immune indications, allowing for greater flexibility and a reduction in cycle times that will provide patients in need with advanced cell therapy treatments at significantly reduced costs.